Loading organizations...
Jebsen Capital is the investment division of the Jebsen Group, focusing on growth equity investments and asset management in promising new industries, based in Hong Kong. The division strengthens its parent group's core businesses while capturing opportunities in innovative sectors, providing market access and strategic investments across Greater China. Jebsen Capital has made notable investments in healthtech, including an early investment in German COVID-19 vaccine manufacturer BioNTech. They also led the Series C extension round for Berlin-based healthtech company PlusDental. Operating as part of the family-owned Jebsen Group, which was founded in 1895 by Jacob Jebsen and Heinrich Jessen, Jebsen Capital was established in 2017. Its business model centers on growth equity investments and in-house asset management, funded as part of the family-owned Jebsen Group.
Key people at Jebsen Capital.
Key people at Jebsen Capital.
Jebsen Capital has 4 tracked investments across 4 companies. The latest tracked deal is $130.0M Series B in Razor Group in November 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2021 | Razor Group | $130.0M Series B | — | General Catalyst, LGF, Presight Capital, Republic Records, Maria Raga, 468 Capital, BlackRock, Fortress Investment Group, Global Founders Capital, Redalpine, Victory Park Capital |
| Mar 1, 2021 | PlusDental | $41.0M Series C | Jebsen Capital | Mario Götze |
| Jul 9, 2019 | BionTTech | $325.0M Series B | Fidelity Management & Research Company | BVCF Management, Invus, Mirae Asset, Platinum Asset Management, Redmile Group, Steam Athena Capital, Struengmann Family Office |
| Oct 23, 2018 | Cipia | $15.0M Other Equity | Arie Capital, Bank Mizrahi, Jebsen Capital | — |
